EMA PRIME Wins For Bispecific Antibodies & Another Gene Therapy

Just three of the 13 applications that the European Medicines Agency most recently reviewed for entry onto its priority medicines scheme made the grade.

airport runway under the sun as background
The PRIME scheme can help get drugs for unmet medical needs to patients faster • Source: Shutterstock

Three new investigational drugs have secured a place on the European Medicines Agency’s PRIME (priority medicines) scheme, including talquetamab and teclistamab, the bispecific antibodies that Janssen is developing to treat relapsed or refractory multiple myeloma.

ARU-1801, Aruvant Sciences’ one-time investigational gene therapy for sickle cell disease, is also among the latest product to win a...

More from Europe

More from Geography